Logo
x

Search

Subscribe Now

Merus

Merus Receives the US FDA’s Breakthrough Therapy Designation for Petosemtamab to Treat 1L PD-L1+ Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Merus Receives the US FDA’s Breakthrough Therapy Designation for Petosemtamab to Treat 1L PD-L1+ Recurrent or Metastatic Head and...

  • February 19, 2025
Merus Reports Dosing of First Patient in P-II Study Evaluating Petosemtamab in 3L+ mCRC

Merus Reports Dosing of First Patient in P-II Study Evaluating Petosemtamab in 3L+ mCRC

  • December 19, 2024
Merus Reports the US FDA’s Accelerated Approval of Bizengri (Zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NSCLC

Merus Reports the US FDA’s Accelerated Approval of Bizengri (Zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NSCLC

  • December 5, 2024
Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer

Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer

  • December 3, 2024
Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and Neck Squamous Cell Carcinoma (HNSCC)

Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and N...

  • October 1, 2024
Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

  • May 14, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.